Eurosurv. Benefits and risks associated with different uses of the COVID-19 vaccine Vaxzevria: a modelling study, France, May to September 2021

[tetano]

• Cécile Tran Kiem[SUP]1,2[/SUP] , Alessio Andronico[SUP]1[/SUP] , Paolo Bosetti[SUP]1[/SUP] , Juliette Paireau[SUP]1,3[/SUP] , Lise Alter[SUP]4[/SUP] , Pierre-Yves Boëlle[SUP]5[/SUP] , Arnaud Fontanet[SUP]6,7[/SUP] , Daniel Lévy-Bruhl[SUP]3[/SUP] , Simon Cauchemez[SUP]1[/SUP]

Thrombosis with thrombocytopenia (TTS) has been identified as a rare adverse event following COVID-19 vaccination with Vaxzevria. We modelled the benefits and risks of Vaxzevria distribution from May to September 2021 in metropolitan France where other vaccines are available, considering French hospitalisation data and European data on TTS. Across different scenarios, benefits of Vaxzevria distribution in people 55 years and older exceeded the risk of death from COVID-19. In young adults, risks were at least of similar magnitude as benefits.

full article

https://www.eurosurveillance.org/content/10.2807/1560-7917.ES.2021.26.26.2100533#html_fulltext